Positions

Overview

  • Introduction:

    I joined UAB after completing my fellowship in hematology-oncology at the Mayo Clinic, MN. I am a physician scientist with focus on lymphoma and histiocytic disorders.

    Clinical interests:

    1) Hodgkin lymphoma,
    2) B-cell non-Hodgkin lymphoma (diffuse large B-cell lymphoma, follicular lymphoma, MALT lymphoma, marginal zone lymphoma, Waldenstrom Macroglobulinemia, chronic lymphocytic leukemia/small lymphocytic lymphoma etc.),
    3) T-cell lymphoma (peripheral T-cell lymphoma, angioimmunoblastic T-cell lymphoma, etc.),
    4) Histiocytosis (Erdheim-Chester disease, Langerhans cell histiocytosis, Rosai-Dorfman disease, histiocytic sarcoma, langerhans cell sarcoma, xanthogranuloma),
    5) HIV-related lymphomas.

    Research:

    I work closely with multiple specialists for the care of patients with these rare diseases, and conduct clinical, translational, and outcomes research to improve patient outcomes.
  • Selected Publications

    Academic Article

    Year Title Altmetric
    2022 Prolonged remission with pembrolizumab and radiation therapy in a patient with multisystem Langerhans cell sarcomaHaematologica: the hematology journal.  107:2276-2279. 2022
    2022 Ophthalmologic involvement in adults with histiocytic disorders: Clinical presentation and treatment outcomes.Ophthalmology2022
    2022 Evaluating real-world treatment patterns and outcomes of mantle cell lymphomaBlood Advances.  6:4122-4131. 2022
    2022 Multimodality imaging of cardiac involvement in Erdheim-Chester diseaseEHJ Cardiovascular Imaging / European Heart Journal - Cardiovascular Imaging.  23:E276. 2022
    2022 Clinical and therapeutic implications of BRAF fusions in histiocytic disordersBlood Cancer Journal.  12. 2022
    2022 Clinical features and outcomes of non-pulmonary unifocal adult Langerhans cell histiocytosisBlood Cancer Journal.  12. 2022
    2022 Near Complete Response to Trametinib Treatment in Histiocytic Sarcoma Harboring a Somatic KRAS MutationJournal of the National Comprehensive Cancer Network : JNCCN.  20:618-621. 2022
    2022 International expert consensus recommendations for the diagnosis and treatment of Langerhans cell histiocytosis in adultsBlood.  139:2601-2621. 2022
    2022 Impact of the COVID-19 Pandemic on Treatment Patterns for Patients With Metastatic Solid Cancer in the United StatesJournal of the National Cancer Institute.  114:571-578. 2022
    2022 Impact of a Multidisciplinary Tumor Board on the Care of Patients with Histiocytic Disorders: The Histiocytosis Working Group experienceThe Oncologist.  27:144-148. 2022
    2022 Sustained, complete response to pexidartinib in a patient with CSF1R-mutated Erdheim–Chester diseaseAmerican Journal of Hematology.  97:293-302. 2022
    2022 Mimics of Erdheim–Chester diseaseBritish Journal of Haematology.  196:984-994. 2022
    2022 Classical and non-classical phenotypes of Erdheim–Chester disease: Correlating clinical, radiographic and genotypic findingsBritish Journal of Haematology2022
    2022 Patterns of Utilization and Outcomes of Autologous Stem Cell Transplantation and Chimeric Antigen Receptor T-Cell Therapy in Relapsed or Refractory Diffuse Large B-cell Lymphomas with MYC and BCL2 and/or BCL6 RearrangementsClinical Lymphoma, Myeloma and Leukemia2022
    2022 Risk of mortality and second malignancies in primary myelofibrosis before and after ruxolitinib approvalLeukemia Research.  112. 2022
    2021 A population-based study of outcomes in polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the United States from 2001 to 2015: Comparison with data from a Mayo Clinic single institutional seriesAmerican Journal of Hematology.  96:E464-E468. 2021
    2021 Langerhans cell histiocytosis with lung involvement in isolation and multisystem disease: Staging, natural history, and comparative survivalAmerican Journal of Hematology.  96:1604-1610. 2021
    2021 Healthcare utilization and spending among older patients diagnosed with Non-Hodgkin lymphomaJournal of Geriatric Oncology.  12:1225-1232. 2021
    2021 Histiocytic neoplasms, version 2.2021Journal of the National Comprehensive Cancer Network : JNCCN.  19:1277-1303. 2021
    2021 Impact of the COVID-19 pandemic on treatment patterns for US patients with metastatic solid cancer. 2021
    2021 CAR T-cell therapy in mature lymphoid malignancies: clinical opportunities and challenges.Annals of translational medicine.  9:1036. 2021
    2021 Immune checkpoint inhibitors in lymphoma: challenges and opportunities.Annals of translational medicine.  9:1037. 2021
    2021 Single-agent cladribine as an effective front-line therapy for adults with Langerhans cell histiocytosisAmerican Journal of Hematology.  96:E146-E150. 2021
    2021 The Tissue Issue: When to Biopsy Persistent or Refractory Disease in Classic Hodgkin LymphomaActa Haematologica.  144:130-131. 2021
    2021 CHIPping away at Erdheim-Chester diseaseBlood.  137:434-436. 2021
    2021 Acute Pancreatitis from Treatment with BRAF Inhibitors in Erdheim-Chester Disease: A Report from 2 Tertiary Referral CentersPancreas.  50:e6-e8. 2021
    2021 Highlights of the Management of Adult Histiocytic Disorders: Langerhans Cell Histiocytosis, Erdheim-Chester Disease, Rosai-Dorfman Disease, and Hemophagocytic LymphohistiocytosisClinical Lymphoma, Myeloma and Leukemia.  21:e66-e75. 2021
    2021 Rosai-dorfman disease displays a unique monocyte-macrophage phenotype characterized by expression of OCT2American Journal of Surgical Pathology.  45:35-44. 2021
    2020 Efficacy of BRAF-Inhibitor Therapy in BRAFV600E-Mutated Adult Langerhans Cell HistiocytosisThe Oncologist.  25:1001-1004. 2020
    2020 T-cell lymphomas, version 1.2021 featured updates to the NCCN guidelinesJournal of the National Comprehensive Cancer Network : JNCCN.  18:1460-1467. 2020
    2020 Low-dose vemurafenib monotherapy in BRAFV600E-mutated Erdheim-Chester diseaseLeukemia and Lymphoma.  61:2733-2737. 2020
    2020 Survival and prognostic factors in patients with rectal squamous cell carcinomaEuropean Journal of Surgical Oncology.  46:1111-1117. 2020
    2020 Erdheim-Chester disease: Consensus recommendations for evaluation, diagnosis, and treatment in the molecular eraBlood.  135:1929-1945. 2020
    2020 Novel staging system using carbohydrate antigen (CA) 19-9 in extra-hepatic cholangiocarcinoma and its implications on overall survival: CA19-9 in the staging of extra-hepatic cholangiocarcinomaEuropean Journal of Surgical Oncology.  46:789-795. 2020
    2020 Primary cutaneous lymphomas, version 2.2020. Featured updates to the NCCN guidelinesJournal of the National Comprehensive Cancer Network : JNCCN.  18:522-536. 2020
    2020 Association between facility volume and mortality of patients with classic Hodgkin lymphomaCancer.  126:757-764. 2020
    2020 43-Year-Old Man With Polyuria and Bone PainMayo Clinic Proceedings.  95:e13-e18. 2020
    2020 Erdheim–Chester disease: expanding the spectrum of cutaneous manifestationsBritish Journal of Dermatology.  182:405-409. 2020
    2020 Bone marrow findings in Erdheim-Chester disease: Increased prevalence of chronic myeloid neoplasmsHaematologica: the hematology journal.  105:84-86. 2020
    2020 Clinicopathological features, treatment approaches, and outcomes in Rosai-Dorfman diseaseHaematologica: the hematology journal.  105:348-357. 2020
    2020 Erdheim-chester disease with concomitant rosai-dorfman like lesions: A distinct entity mainly driven by MAP2K1Haematologica: the hematology journal.  105:E5-E8. 2020
    2019 Inter-axonal recognition organizes Drosophila olfactory map formationScientific Reports.  9. 2019
    2019 Sphingolipid-dependent Dscam sorting regulates axon segregationNature Communications.  10. 2019
    2019 Concomitant Erdheim-Chester disease and chronic myelomonocytic leukaemia: genomic insights into a common clonal originBritish Journal of Haematology.  187:e51-e54. 2019
    2019 The Mayo Clinic Histiocytosis Working Group Consensus Statement for the Diagnosis and Evaluation of Adult Patients With Histiocytic Neoplasms: Erdheim-Chester Disease, Langerhans Cell Histiocytosis, and Rosai-Dorfman DiseaseMayo Clinic Proceedings.  94:2054-2071. 2019
    2019 Neoadjuvant vs. adjuvant chemotherapy for cholangiocarcinoma: A propensity score matched analysisEuropean Journal of Surgical Oncology.  45:1432-1438. 2019
    2019 Incidence, Clinical Features, and Outcomes of Langerhans Cell Sarcoma in the United StatesClinical Lymphoma, Myeloma and Leukemia.  19:441-446. 2019
    2019 Autoimmune encephalitis secondary to melanomaAnnals of Internal Medicine.  170:905-906. 2019
    2019 Phase 1 trial of enzalutamide in combination with gemcitabine and nab-paclitaxel for the treatment of advanced pancreatic cancerInvestigational New Drugs.  37:473-481. 2019
    2019 Impact of prior diagnosis of monoclonal gammopathy on outcomes in newly diagnosed multiple myelomaLeukemia.  33:1273-1277. 2019
    2019 Tumor mutational burden and other predictive immunotherapy markers in histiocytic neoplasmsBlood.  133:1607-1610. 2019
    2019 A population-based analysis of second primary malignancies in T-cell neoplasmsBritish Journal of Haematology.  185:338-342. 2019
    2019 T cell/histiocyte-rich large B cell lymphoma: incidence, demographic disparities, and long-term outcomesBritish Journal of Haematology.  185:140-142. 2019
    2019 Association between treatment facility volume, therapy types and overall survival in patients with intrahepatic cholangiocarcinomaHepato Pancreato Biliary.  21:379-386. 2019
    2019 Predictors of survival, treatment patterns, and outcomes in histiocytic sarcomaLeukemia and Lymphoma.  60:553-555. 2019
    2019 Clinicopathological features and outcomes of fibrolamellar hepatocellular carcinomaJournal of Gastrointestinal Oncology.  10:554-561. 2019
    2019 Editorial plasmacytomas: Many faces of one disease, or many diseases with one face?Oncotarget.  10:257-258. 2019
    2019 Improved interpretability of machine learning model using unsupervised clustering: Predicting time to first treatment in chronic lymphocytic leukemiaJCO Clinical Cancer Informatics.  3:1-11. 2019
    2018 Arterial involvement in Erdheim-Chester disease A retrospective cohort studyMedicine.  97. 2018
    2018 Efficacy of biological agents in the treatment of Erdheim-Chester diseaseBritish Journal of Haematology.  183:520-524. 2018
    2018 A prognostic scoring model for survival after locoregional therapy in de novo stage IV breast cancerBreast Cancer Research and Treatment.  170:677-685. 2018
    2018 Adult disseminated Langerhans cell histiocytosis: incidence, racial disparities and long-term outcomesBritish Journal of Haematology.  182:579-581. 2018
    2018 Association between hospital volume and mortality of patients with metastatic non-small cell lung cancerLung Cancer.  122:214-219. 2018
    2018 Florid dermatopathic lymphadenopathy—A morphological mimic of Langerhans cell histiocytosisClinical Case Reports.  6:1637-1638. 2018
    2018 Treatment approaches and outcomes in plasmacytomas: Analysis using a national datasetLeukemia.  32:1414-1420. 2018
    2018 Neuroradiologic manifestations of Erdheim-Chester diseaseNeurology: Clinical Practice.  8:15-20. 2018
    2018 Contemporary management of localized resectable pancreatic cancerCancers.  10. 2018
    2018 Histiocytic sarcoma: A population-based analysis of incidence, demographic disparities, and long-term outcomesBlood.  131:265-268. 2018
    2017 Clinical and radiological responses to oral methotrexate alone or in combination with other agents in erdheim-chester diseaseBlood Cancer Journal.  7. 2017
    2017 Treatment Patterns and Outcomes in Early-stage Hodgkin Lymphoma in the Elderly: A National Cancer Database AnalysisClinical Lymphoma, Myeloma and Leukemia.  17:812-818. 2017
    2017 Clinical and radiologic responses to cladribine for the treatment of Erdheim-Chester diseaseJAMA Oncology.  3:1253-1256. 2017
    2017 Clinical features and outcomes of extramedullary myeloid sarcoma in the United States: Analysis using a national data setBlood Cancer Journal.  7. 2017
    2016 Composite lymphoma with diffuse large B-cell lymphoma and classical Hodgkin lymphoma components: A case report and review of the literaturePathology, Research and Practice.  212:1179-1190. 2016
    2016 Hereditary cancer syndromes: utilizing DNA repair deficiency as therapeutic targetFamilial Cancer.  15:359-366. 2016
    2016 Acquired haemophilia A: An unusual postoperative complicationBMJ Case Reports.  2016. 2016
    2016 Trends in Use of Radiation Therapy for Hodgkin Lymphoma from 2000 to 2012 on the Basis of the National Cancer Data BaseClinical Lymphoma, Myeloma and Leukemia.  16:12-17. 2016
    2015 Salivary gland cancers: Biology and systemic therapyOncology (Williston Park, N.Y.).  29:773-780. 2015
    2015 L-asparaginase and venous thromboembolism in acute lymphocytic leukemiaFuture Oncology.  11:2459-2470. 2015
    2015 Double-Hit LymphomaJournal of Clinical and Experimental Hematopathology.  55:51-53. 2015
    2015 Multicentric Castleman Disease with Monoclonal Incomplete IgH Restriction: A Rare CoexistenceJournal of Clinical and Experimental Hematopathology.  55:103-108. 2015
    2007 Role of Mitochondrial Remodeling in Programmed Cell Death in Drosophila melanogasterDevelopmental Cell.  12:807-816. 2007

    Principal Investigator On

  • A Multicenter Retrospective Analysis of Treatment Patterns and Outcomes in Patients with Rare T-Cell Lymphoma Subtypes  awarded by Memorial Sloan-Kettering Cancer Center
  • A Multicenter Retrospective Analysis of Treatment Patterns and Outcomes in Patients with Rare T-Cell Lymphoma Subtypes  awarded by NHS GREATER GLASGOW AND CLYDE
  • A Multicenter Retrospective Study of Outcomes of High-Grade B Cell Lymphoma with BCL2 Or BCL6 And MYC Rearrangements After First Relapse  awarded by University of Minnesota
  • Burden of Morbidity and Premature Mortality in Patients with Langerhans Cell Histiocytosis  awarded by Histiocytosis Association of America
  • Determinants of Efficacy and Toxicities among Patients with Lymphoid and Histiocytic Disorders  awarded by Memorial Sloan-Kettering Cancer Center
  • Nacho-Bio: A Translational Biology Platform To Advance Understanding Of Pathogenesis And Improve Outcomes For Patients With Histiocytic Disorders  awarded by St. Jude Children's Research Hospital
  • Private Grant  awarded by SUTRO BIOPHARM
  • Private Grant  awarded by Genentech
  • Private Grant  awarded by SEATTLE GENETICS, INC.
  • Private Grant  awarded by INNATE PHARMA
  • Private Grant  awarded by VIRACTA INC
  • Project Burden of Morbidity and Premature Mortality in Patients with Erdheim-Chester Disease  awarded by Uplifting Athletes
  • XUAB 2069: Phase I Study of MK-3475 (Pembrolizumab) in Patients with Human Immunodeficiency Virus (HIV) and Relapsed/Refractory or Disseminated Malignant Neoplasm  awarded by Hutchinson (Fred) Cancer Research Center
  • Investigator On

  • Comprehensive Cancer Center Core Support Grant  awarded by National Cancer Institute/NIH/DHHS
  • Deep Phenotyping of Reportable Cancer Recurrence  awarded by BOSTON CHILDREN'S HOSPITAL
  • ECOG-ACRIN Purchase Service Agreement  awarded by Eastern Cooperative Oncology Group
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC
  • Private Grant  awarded by F.Hoffmann-La Roche Ltd.
  • Private Grant  awarded by MERCK SHARP & DOHME CORP
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY
  • Private Grant  awarded by F.Hoffmann-La Roche Ltd.
  • Private Grant  awarded by Genentech
  • Private Grant  awarded by Genentech
  • Private Grant  awarded by Genentech
  • Private Grant  awarded by ASTEX PHARMACEUTICALS
  • Private Grant  awarded by MILLENNIUM PHARMACEUTICALS, INC.
  • Private Grant  awarded by INCYTE CORPORATION
  • Private Grant  awarded by Gilead Sciences ^
  • Private Grant  awarded by SEATTLE GENETICS, INC.
  • Private Grant  awarded by TG THERAPEUTICS
  • Private Grant  awarded by JUNO THERAPEUTICS
  • Private Grant  awarded by INNATE PHARMA
  • Private Grant  awarded by AFFIMED GMBH
  • Private Grant  awarded by CAREVIVE SYSTEMS, INC.
  • Private Grant  awarded by MILLENNIUM PHARMACEUTICALS, INC.
  • Private Grant  awarded by JUNO THERAPEUTICS
  • Private Grant  awarded by SEATTLE GENETICS, INC.
  • Private Grant  awarded by TG THERAPEUTICS
  • Private Grant  awarded by SEATTLE GENETICS, INC.
  • Private Grant  awarded by AMGEN, INC.^
  • Private Grant  awarded by INCYTE CORPORATION
  • Private Grant  awarded by GENMAB
  • Private Grant  awarded by GENMAB
  • Private Grant  awarded by Genentech
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC
  • Private Grant  awarded by Gilead Sciences ^
  • Private Grant  awarded by FATE THERAPEUTICS, INC.
  • Private Grant  awarded by ARTIVA BIOTHERAPEUTICS INC
  • Private Grant  awarded by JUNO THERAPEUTICS
  • Private Grant  awarded by TG THERAPEUTICS
  • Private Grant  awarded by INCYTE CORPORATION
  • Private Grant  awarded by INCYTE CORPORATION
  • Private Grant  awarded by TAKEDA DEVELOPMENT CENTER AMERICAS, INC.
  • Private Grant  awarded by ROCHE PHARMACEUTICAL
  • Private Grant  awarded by CELGENE CORPORATION
  • Private Grant  awarded by ONO PHARMACEUTICAL COMPANY LTD
  • Private Grant  awarded by INNATE PHARMA
  • Private Grant  awarded by Genentech
  • Private Grant  awarded by I-MAB BIOPHARMA US LIMITED
  • SWOG Purchase Services Agreement  awarded by Oregon Health & Science University
  • UAB 1923: A Phase 2 Front-Line PET/CT-2 Response-Adapted Brentuximab Vedotin and Nivolumab Incorporated and Radiation-Free Management of Early Stage Classical Hodgkin Lymphoma (cHL) study  awarded by City of Hope
  • Education And Training

  • Bachelor of Medicine & Surgery (MBBS), 2012
  • Full Name

  • Gaurav Goyal